留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

实体器官移植与骨质疏松

蓝恭斌 彭龙开 张红

蓝恭斌, 彭龙开, 张红. 实体器官移植与骨质疏松[J]. 器官移植, 2015, 6(5): 283-287. doi: 10.3969/j.issn.1674-7445.2015.05.001
引用本文: 蓝恭斌, 彭龙开, 张红. 实体器官移植与骨质疏松[J]. 器官移植, 2015, 6(5): 283-287. doi: 10.3969/j.issn.1674-7445.2015.05.001

实体器官移植与骨质疏松

doi: 10.3969/j.issn.1674-7445.2015.05.001
基金项目: 

湖南省发展与改革委员会高科技项目 2009-1390

详细信息
    通讯作者:

    彭龙开, 医学博士, 主任医师, 教授, 博士研究生导师, 国内知名肾移植专家。现任中南大学湘雅二医院器官移植中心副主任, 泌外器官移植科主任。兼任中国肾移植科学登记系统管理委员会委员、中国医师协会器官移植分会肾移植专业委员会委员、中国透析移植研究会委员、湖南省器官移植医疗质量控制中心主任、湖南省人体器官获取组织专家组组长、湖南省器官移植专业委员会副主任委员、湖南省临床免疫学专业委员会委员、湖南省计划生育技术专业委员会委员。兼任《中南大学学报:医学版》、《中国医师杂志》、《中国组织工程研究》、《器官移植当代视点》、《肾友》等杂志编委或审稿人, 同时兼任湖南省自然科学基金、湖南省医学科技奖等评委。主持开展人体器官捐献工作, 完成公民逝世后器官捐献150余例, 儿童心脏死亡后器官捐献(DCD)供肾移植成绩突出, 尤其对婴幼儿双肾供肾移植有较深研究, 处于国内领先地位, 后腹腔镜亲属活体供肾切取手术也处于国内先进水平。除从事肾移植基础和临床研究工作外, 还擅长各种高难度的泌尿外科手术, 尤其是肾上腺疾病、前列腺疾病、泌尿系肿瘤的诊治。主持省部级课题6项, 共发表论文50余篇, 其中科学引文索引(Science Citation Index, SCI)论文10余篇, 参编著作5部。培养博士研究生7名, 硕士研究生8名.Email:PLK3000@163.com

  • 中图分类号: R617;R681

  • 摘要: 骨质疏松是实体器官移植术后常见的并发症之一, 常发生于术后第6~12个月, 轻者可无明显症状和体征, 稍重者表现为腰背疼痛、乏力或全身骨痛, 严重者发生骨折。发病机制主要是骨吸收增加和骨形成减少。术前存在的骨代谢性疾病和术后大量应用免疫抑制剂是实体器官移植患者发病的主要原因。各种实体器官如肾、肝、肺移植术后骨质疏松的发病原因、发病特点各不相同。骨质疏松的防治除了应用一般防治措施外, 还可应用钙、维生素D、活性维生素D、双膦酸盐类药物、降钙素、甲状旁脉激素及激素替代治疗等。控制肾上腺皮质激素用量是预防骨质疏松的关键措施。

     

  • [1] Yu TM, Lin CL, Chang SN, et al. Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study [J].Mayo Clin Proc, 2014, 89(7):888-895. doi: 10.1016/j.mayocp.2014.02.017
    [2] Soriano R, Herrera S, Nogués X, et al. Current and future treatments of secondary osteoporosis [J].Best Pract Res Clin Endocrinol Metab, 2014, 28(6):885-894. doi: 10.1016/j.beem.2014.09.004
    [3] Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis [J].Bone, 2011, 48(6):1221-1231. doi: 10.1016/j.bone.2011.02.005
    [4] Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies [J].Thorax, 2011, 66(8):699-708. doi: 10.1136/thx.2011.160028
    [5] Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells [J].Mol Endocrinol, 2009, 23(10):1525-1531. doi: 10.1210/me.2009-0069
    [6] Saidak Z, Le Henaff C, Azzi S, et al. Wnt/β-catenin signaling mediates osteoblast differentiation triggered by peptide-induced α5β1 integrin priming in mesenchymal skeletal cells [J].J Biol Chem, 2015, 290(11):6903-6912. doi: 10.1074/jbc.M114.621219
    [7] Liou SF, Hsu JH, Chu HC, et al. KMUP-1 Promotes Osteoblast Differentiation Through cAMP and cGMP Pathways and Signaling of BMP-2/Smad1/5/8 and Wnt/β-Catenin [J].J Cell Physiol, 2015, 230(9):2038-2048. doi: 10.1002/jcp.24904
    [8] Clarke BL. Corticosteroid-induced osteoporosis: an update for dermatologists [J].Am J Clin Dermatol, 2012, 13(3):167-190. doi: 10.2165/11594250-000000000-00000
    [9] Chen Y, Zheng X, Zou R, et al. Effects of cyclosporin-a on rat skeletal biomechanical properties [J].BMC Musculoskelet Disord, 2011, 12:240. doi: 10.1186/1471-2474-12-240
    [10] Ponticelli C, Aroldi A. Osteoporosis after organ transplantation [J].Lancet, 2001, 357(9268):1623. doi: 10.1016/S0140-6736(00)04767-X
    [11] Aroldi A, Tarantino A, Montagnino G, et al. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study [J].Transplantation, 1997, 63(3):380-386. doi: 10.1097/00007890-199702150-00009
    [12] Monegal A, Navasa M, Guañabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A [J].Calcif Tissue Int, 2001, 68(2):83-86. doi: 10.1007/BF02678145
    [13] Luo L, Shi Y, Bai Y, et al. Impact of tacrolimus on bone metabolism after kidney transplantation [J].Int Immunopharmacol, 2012, 13(1):69-72. doi: 10.1016/j.intimp.2012.03.019
    [14] Westenfeld R, Schlieper G, Wöltje M, et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis: implications for post-transplantation bone disease [J].Nephrol Dial Transplant, 2011, 26(12):4115-4123. doi: 10.1093/ndt/gfr214
    [15] Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients [J].Am J Kidney Dis, 2013, 61(2):310-325. doi: 10.1053/j.ajkd.2012.07.022
    [16] Pereira S, Pedroso S, Martins L, et al. Bone mineral density after simultaneous kidney-pancreas transplantation: four years follow-up of 57 recipients [J].Transplant Proc, 2010, 42(2):555-557. doi: 10.1016/j.transproceed.2010.01.046
    [17] Falkiewicz K, Boratyńska M, Zmonarski SC, et al. Evolution of bone disease at 2 years after transplantation: a single-center study [J].Transplant Proc, 2009, 41(8):3063-3066. doi: 10.1016/j.transproceed.2009.09.041
    [18] Wang TK, O′Sullivan S, Gamble GD, et al. Bone density in heart or lung transplant recipients: a longitudinal study [J].Transplant Proc, 2013, 45(6):2357-2365. doi: 10.1016/j.transproceed.2012.09.117
    [19] Dolgos S, Hartmann A, Isaksen GA, et al. Osteoporosis is a prevalent finding in patients with solid organ failure awaiting transplantation: a population based study [J].Clin Transplant, 2010, 24(5):E145-E152. doi: 10.1111/ctr.2010.24.issue-5
    [20] Ebeling PR. Approach to the patient with transplantation-related bone loss [J].J Clin Endocrinol Metab, 2009, 94(5):1483-1490. doi: 10.1210/jc.2009-0205
    [21] Dalle Carbonare L, Zanatta M, Braga V, et al. Densitometric threshold and vertebral fractures in heart transplant patients [J].Transplantation, 2011, 92(1):106-111. doi: 10.1097/TP.0b013e31821cdeef
    [22] Hariman A, Alex C, Heroux A, et al. Incidence of fractures after cardiac and lung transplantation: a single center experience [J].J Osteoporos, 2014:573041. https://www.ncbi.nlm.nih.gov/pubmed/24864223
    [23] Cahill BC, O'Rourke MK, Parker S, et al. Prevention of bone loss and fracture after lung transplantation: a pilot study [J].Transplantation, 2001, 72(7):1251-1255. doi: 10.1097/00007890-200110150-00012
    [24] Ewers B, Gasbjerg A, Moelgaard C, et al. Vitamin D status in kidney transplant patients: need for intensified routine supplementation [J].Am J Clin Nutr, 2008, 87(2):431-437. https://www.ncbi.nlm.nih.gov/pubmed/18258635
    [25] Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation [J].J Bone Miner Res, 2000, 15(9):1818-1824. doi: 10.1359/jbmr.2000.15.9.1818
    [26] Lan G, Peng L, Xie X, et al. Alendronate is effective to treat bone loss in renal transplantation recipients [J].Transplant Proc, 2008, 40(10):3496-3498. doi: 10.1016/j.transproceed.2008.09.034
    [27] Wang Z, Han Z, Tao J, et al. Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials [J].PLoS One, 2014, 9(9):e108106. doi: 10.1371/journal.pone.0108106
    [28] Monegal A, Guañabens N, Suárez MJ, et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial [J].Transpl Int, 2009, 22(2):198-206. doi: 10.1111/j.1432-2277.2008.00763.x
    [29] Wang HH, Chang PC, Chu SH, et al. Osteoporosis after kidney transplantation: preliminary report from a single center [J].Transplant Proc, 2008, 40(7):2412-2413. doi: 10.1016/j.transproceed.2008.06.042
    [30] Cejka D, Benesch T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation [J].Am J Transplant, 2008, 8(9):1864-1870. doi: 10.1111/ajt.2008.8.issue-9
    [31] Isoniemi H, Appelberg J, Nilsson CG, et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. a 2-year follow-up study [J].J Hepatol, 2001, 34(2):299-305. doi: 10.1016/S0168-8278(00)00067-2
  • 加载中
计量
  • 文章访问数:  139
  • HTML全文浏览量:  46
  • PDF下载量:  23
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-08-01
  • 网络出版日期:  2021-04-29
  • 刊出日期:  2015-09-01

目录

    /

    返回文章
    返回